REG - Mast Energy Dvlpmts. - Revenues Update

Mast Energy DevelopmentsAnnouncement

Thu 07:01

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250731:nRSe2790Ta&default-theme=true

RNS Number : 2790T  Mast Energy Developments PLC  31 July 2025

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

LEI :213800HFVHGJ9YGO9F71

Share code on the LSE: MAST

ISIN: GB00BNG90H86

('MED' or 'the Company')

 

Dated: 31 July 2025

 

Mast Energy Developments PLC

 

Revenues Update

and Appointment of Investor Relations Firm

 

Mast Energy Developments PLC ("MED" or the "Company") is pleased to announce
an update regarding its wholly owned Pyebridge flexible generation power
station including latest revenues generated for the first half of 2025, as
well as the appointment of a strategic investor relations firm, the highlights
and details of which are outlined below.

 

Pyebridge Update:

·    MED's 100% owned Pyebridge asset generated and sold c. 4.09
Gigawatt/hours ("GWh") of electricity during the first 6-months of 2025, an
increase of c. 0.93 GWh or c. 30% compared to the preceding 6-month period;

·    Pyebridge generated and sold c. 7.3 GWh of electricity during the
12-month period ending June 2025;

·    Total revenues generated for the first 6-months of 2025 came to c.
£746,000, an increase of c. 30% compared to the preceding 6-month period;

·    Total revenues based on an average of 5.4 MW in production,
representing c. £23k per MW per month;

·    Pyebridge average actual electricity sales price achieved during
first 6-months of 2025 equates to c. £157 MWh, representing a c. 76%
outperformance compared to the average wholesale market electricity price over
the same period;

·    Pyebridge project finance debt facility with RiverFort total historic
draws equals c. £2.77m, of which c. £870k or c. 31% has been repaid over the
past 12 months from cash generated by Pyebridge (including VAT refunds); and

·    MED management is planning to apply for a final T-4 Capacity Market
("CM") contract for Pyebridge in the upcoming CM prequalification window, with
the intention of obtaining a maximum 15-year term CM contract, to supplement
Pyebridge's existing CM contracts which cover the periods up to 2029, meaning
if the final contract is obtained Pyebridge will have uninterrupted guaranteed
CM gross income payments until 2044.

 

Pieter Krügel, MED CEO, commented: "We are very proud of the ongoing and
increasing positive results from our Pyebridge asset. It is clear that the
refurbishment programme launched on the site earlier in 2024 was a success.
The ongoing positive results from Pyebridge provides a solid foundation and a
clear indication of what we can expect from our further sites that will go
into production and revenue generation going forward.

 

With the acquisition of the exclusive rights to a portfolio of development
sites as recently announced, effectively doubling MED's portfolio of sites to
c. 48 MW once developed, and scalable to 100 MW in the near term, we are
making tremendous progress toward our goal of building a portfolio of 300+ MW.

 

We are looking forward to providing the market with further positive updates
over the coming weeks."

 

Appointment of Strategic Investor Relations Firm

MED is pleased to announce the appointment of Fairfax Partners Inc., a
boutique investor relations firm, to enhance the Company's international
communications and investor outreach. The firm will be supporting MED and its
existing partners with tailored investor engagement and communications
designed to enhance international visibility and ensure consistent,
high-quality communication with the investment community as the Company
advances its strategy of building a portfolio of 300+ MW. As part of this
initiative, Fairfax will develop marketing materials including landing pages,
investor presentations, and targeted outreach campaigns which fully articulate
the current and future interests of MED.

 

 

Stay up to date with MED's latest news and updates by joining our emailing
list and social media channels, as follows:

 

MED general enquiries - https://www.med.energy/contact
(https://www.med.energy/contact)

MED email alerts - https://www.med.energy/rnsannoucements-1
(https://www.med.energy/rnsannoucements-1)

MED LinkedIn page -
https://uk.linkedin.com/company/mast-energy-developments-plc
(https://uk.linkedin.com/company/mast-energy-developments-plc)

MED X (formerly Twitter) handle - @mastplc

 

 

ENDS

 

This announcement contains inside information for the purposes of the UK
version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ('UK MAR'). Upon the publication of this announcement, this inside
information is now considered to be in the public domain.

 

For further information please visit www.med.energy (http://www.med.energy/)
or contact:

 Pieter Krügel      info@med.energy (mailto:info@med.energy)  Mast Energy           CEO

                                                              Developments PLC
 Guy Wheatley, CFA  +44 (0)74 9398 9014                       Fortified Securities  Corporate Broker
 Jon Belliss        +44 (0)20 7399 9425                       Novum Securities      Corporate Broker

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCDBLFXEDLLBBB